Clinical trial
uPAR in Blood From Zytiga® (Abiraterone) Treated Patients With Castration Resistant Prostate Cancer - a Predictive Marker of Response?
NCT02125617 is registered in ClinicalTrials.gov with Kristoffer Rohrberg as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- uPAR in Blood From Zytiga® (Abiraterone) Treated Patients With Castration Resistant Prostate Cancer - a Predictive Marker of Response?
- Lead sponsor
- Kristoffer Rohrberg
- Phase
- Observational
- Overall status
- Terminated
- Start date
- January 31, 2014
- Completion date
- February 14, 2017
- Enrollment
- 3 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.